These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27154568)

  • 1. Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer.
    Lee JY; Park KS; Lee HG; Baek WK; Cho KB; Lee YJ; Lee YS; Ryu SW
    Clin Exp Med; 2017 Aug; 17(3):403-410. PubMed ID: 27154568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening.
    Aikou S; Ohmoto Y; Gunji T; Matsuhashi N; Ohtsu H; Miura H; Kubota K; Yamagata Y; Seto Y; Nakajima A; Goldenring JR; Kaminishi M; Nomura S
    Gastroenterology; 2011 Sep; 141(3):837-845.e1-7. PubMed ID: 21699780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic value of serum trefoil factor 3 and pepsinogen combination in chronic atrophic gastritis: a retrospective study based on a gastric cancer screening cohort in the community population.
    Zhao J; Tian W; Zhang X; Dong S; Shen Y; Gao X; Yang M; Lv J; Hu F; Han J; Zhan Q; An F
    Biomarkers; 2024 Sep; 29(6):384-392. PubMed ID: 39234749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk.
    Kaise M; Miwa J; Tashiro J; Ohmoto Y; Morimoto S; Kato M; Urashima M; Ikegami M; Tajiri H
    J Gastroenterol; 2011 Jun; 46(6):736-45. PubMed ID: 21455714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China.
    Huang Z; Zhang X; Lu H; Wu L; Wang D; Zhang Q; Ding H
    BMC Gastroenterol; 2014 Apr; 14():74. PubMed ID: 24720760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker.
    Kaise M; Miwa J; Fujimoto A; Tashiro J; Tagami D; Sano H; Ohmoto Y
    Gastric Cancer; 2013 Jul; 16(3):329-37. PubMed ID: 22907485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of serum pepsinogen levels and quininium resin test combined for gastric cancer screening.
    Kim JR; Lee K; Jung WT; Lee OJ; Kim TH; Kim HJ; Lee JS; Passaro DJ
    Cancer Detect Prev; 2005; 29(6):570-5. PubMed ID: 16289505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening Biomarker as an Alternative to Endoscopy for the Detection of Early Gastric Cancer: The Combination of Serum Trefoil Factor Family 3 and Pepsinogen.
    Lee HS; Jeon SW; Nomura S; Seto Y; Kwon YH; Nam SY; Ishibashi Y; Ohtsu H; Ohmoto Y; Yang HM
    Gastroenterol Res Pract; 2018; 2018():1024074. PubMed ID: 29977284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm.
    Choi HS; Lee SY; Kim JH; Sung IK; Park HS; Shim CS; Jin CJ
    J Dig Dis; 2014 Jun; 15(6):293-8. PubMed ID: 24602176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on the cut-off value of serum pepsinogen abnormality for screening chronic atrophic gastritis and gastric carcinoma].
    Li YH; Zhang XH; Huang B; Wang JL; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Oct; 27(10):840-4. PubMed ID: 17343174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation of serum pepsinogen level and gastric mucosal changes of residents in the high incidence area of gastric cancer].
    Zhang XH; Huang B; Wang JL; Li YH; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):507-11. PubMed ID: 17147114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis.
    Haj-Sheykholeslami A; Rakhshani N; Amirzargar A; Rafiee R; Shahidi SM; Nikbin B; Khosravi F; Massarrat S
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):174-9. PubMed ID: 18237867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum pepsinogen levels can quantify the risk of development of metachronous gastric cancer after endoscopic resection.
    Iguchi M; Kato J; Yoshida T; Yamamoto Y; Nakachi K; Fukatsu K; Mori Y; Maeda Y; Moribata K; Shingaki N; Niwa T; Deguchi H; Inoue I; Maekita T; Tamai H; Ichinose M
    Int J Cancer; 2016 Sep; 139(5):1150-6. PubMed ID: 27083518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].
    Gong YH; Sun LP; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):691-3. PubMed ID: 17274377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis].
    Chae H; Lee JH; Lim J; Kim M; Kim Y; Han K; Kang CS; Shim SI; Kim JI; Park SH
    Korean J Lab Med; 2008 Jun; 28(3):201-6. PubMed ID: 18594172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric cancer screening using the serum pepsinogen test method.
    Miki K
    Gastric Cancer; 2006; 9(4):245-53. PubMed ID: 17235625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica.
    Con SA; Con-Wong R; Con-Chin GR; Con-Chin VG; Takeuchi H; Valerín AL; Echandi G; Mena F; Brenes F; Yasuda N; Araki K; Sugiura T
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2631-6. PubMed ID: 18086767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm.
    Boda T; Ito M; Yoshihara M; Kitamura Y; Matsuo T; Oka S; Tanaka S; Chayama K
    Helicobacter; 2014 Feb; 19(1):1-8. PubMed ID: 24215601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
    Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between pepsinogen I/II ratio and age or upper gastrointestinal diseases in Helicobacter pylori-positive and -negative subjects].
    Paik CN; Chung IS; Nam KW; Kwon JH; Chang JH; Suh JP; Park JM; Cho YK; Lee IS; Kim SW; Choi MG
    Korean J Gastroenterol; 2007 Aug; 50(2):84-91. PubMed ID: 17928751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.